Victoria Vakiener served as Chief Commercial Officer of Epizyme, Inc. (2018-2021), a biopharmaceutical company that was acquired in 2022, where she built the commercial organization and launched TAZVERIK for two indications within six months.  Prior to joining Epizyme, Ms. Vakiener was an executive at Johnson & Johnson (NYSE: JNJ) for more than twenty years, where she held positions of leadership with increasing responsibility across the company’s pharmaceutical and diagnostics businesses. She started her pharmaceutical career at Schering-Plough, where she spent nine years in both scientific and commercial roles. 

Ms. Vakiener currently serves on the board of Chimerix (NASDAQ: CMRX), a clinical-stage biopharmaceutical company.

Victoria Vakiener holds a BS in Biochemistry from Albright College.